ClinicalTrials.Veeva

Menu

Long-acting Parasternal Blocks for Analgesia After Cardiac Surgery

J

Jewish General Hospital

Status and phase

Completed
Phase 3

Conditions

Coronary Artery Bypass Graft Surgery

Treatments

Drug: Standard of care
Drug: Parasternal blocks

Study type

Interventional

Funder types

Other

Identifiers

NCT05191745
2022-3125

Details and patient eligibility

About

This is a randomized, double-blind, controlled clinical trial is to evaluate the duration of efficacy of parasternal blocks with the use of local anesthetic adjuncts for analgesia after coronary artery bypass grafting surgery.

Full description

This study will randomize patients to either standard pain control protocols or parasternal blocks after coronary artery bypass grafting-only surgery. This study will specifically examine the effectiveness and duration of analgesia of parasternal blocks with local anesthetic adjuncts, Dexamethasone 10mg and Dexmedetomidine 50mcg, added to the local anesthetic mixture

Enrollment

60 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients coming for elective and urgent coronary artery bypass (CABG)-only surgery.

Exclusion criteria

  • Patients with a history of regular opioid use.
  • Patients with a history of chronic pain.
  • Patients unable to provide consent.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 2 patient groups, including a placebo group

Intervention group
Experimental group
Description:
Patients will receive bilateral parasternal blocks at the end of cardiac surgery.
Treatment:
Drug: Parasternal blocks
Control group
Placebo Comparator group
Description:
Patients will receive all standard care as per the hospital protocols.
Treatment:
Drug: Standard of care

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems